Company: TGE
Filing Date: 2025-01-27
Form Type: 425
Source: 0001213900-25-006756
Chunk: 81

Company: Generation Essentials Group
Filing Date: 2025-01-27
Form: 425
Chunk 81
---
 conflict with
or violate any provision of, or result in the breach of, any Applicable Law, or the BSII Governing Document, (b) assuming the receipt
of the consents, approvals, authorizations and other requirements set forth in ‎Section 6.03, conflict with, violate or result
in a breach of any term, condition or provision of any material Contract to which BSII is a party or by which BSII is bound, or terminate
or result in a default under, or require any consent, notice or other action by any Person under (with or without notice or lapse of time,
or both) or the loss of any right under, or create any right of termination, acceleration or cancellation of any such material Contract,
or (c) result in the creation of any Lien (except for Permitted Liens) upon any of the properties or assets of BSII or constitute
an event which, after notice or lapse of time or both, would reasonably be expected to result in any such violation, breach, termination
or creation of a Lien, except in each case of clauses (a), (b) and (c) above to the extent that the occurrence of each of the
foregoing would not reasonably be expected to have a BSII Material Adverse Effect.

Section 6.05. Litigation and Proceedings. There are no Actions or, to the knowledge of BSII, investigations pending before or by any Governmental Authority
or, to the knowledge of BSII, threatened, against BSII or any of its properties or assets, or, to the knowledge of BSII, any of its directors
or employees, in their capacity as such, that would reasonably be expected to have, individually or in the aggregate, a BSII Material
Adverse Effect or which in any manner challenges or seeks to prevent or enjoin the transactions contemplated hereby. There is no unsatisfied
judgment or any open injunction binding upon BSII. Neither BSII nor any property or asset of BSII has been subject to any Governmental
Order that would reasonably be expected to have a BSII Material Adverse Effect.

<div align='center'>61</div>

Section 6.06. BSII Capitalization.

(a) As
of the date hereof, the authorized share capital of BSII consists of (i) 150,000,000 BSII Class A Ordinary Shares, of
which 15,300,000 BSII Class A Ordinary Shares are issued and outstanding